Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01831882 · ClinicalTrials.gov registry record
Identifying Biological Markers for Severe Depression
A clinical trial, sponsored by Stanford University.
- Completed
- Registry status
- 210
- Enrollment target
NCT01831882: Completed study, sponsored by Stanford University.
NCT01831882 is a clinical trial that has completed, run by Stanford University. The registered enrollment target is 210 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01831882 has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 210 participants
- Enrollment target
Study Summary
The primary objective of this study is to investigate the biological components of major depression. The investigators are particularity interested in genetic variation and how it contributes to cortisol (because cortisol is higher in severe depression than mild depression or healthy controls) and how it contributes to clinical symptoms, especially suicidal ideation/behavior and psychosis.
Primary Outcome
Blood will be drawn for gene expression, which includes genetics and metallothionein assessments. Blood will also be drawn for later assay of immune function/measures and neurotophins, and for future studies.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2013-07 |
| Est. Completion | 2020-08 |
What the finished NCT01831882 record still lists
NCT01831882 is an observational study that tracks outcomes without assigning an intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT01831882 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01831882 about?
NCT01831882 is a clinical study titled "Identifying Biological Markers for Severe Depression". The primary objective of this study is to investigate the biological components of major depression. The investigators are particularity interested in genetic variation and how it contributes to cortisol (because cortisol is higher in severe depression than mild depression or healthy controls) and h...
What is the current status of trial NCT01831882?
This trial is currently completed. The enrollment target is 210 participants. The study started on 2013-07. Estimated completion is 2020-08.
Who is sponsoring clinical trial NCT01831882?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
- NCT03544489 · 210 participants · Phase 2
Effectiveness of Exercise After an ICD
- NCT04408430 · 210 participants · NA
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia